Clinical Publication
RSSArticles
-
Extra Coronary Vascular Involvement in Spontaneous Coronary Artery Dissection
When viewing cardiac MRI and peripheral angiography of patients with spontaneous coronary artery dissection, investigators observed peripheral arterial abnormalities, including fibromuscular dysplasia, in about one-quarter.
-
Searching for the Best Echo Parameter to Predict Aortic Stenosis Outcomes
In a study of two large echocardiographic databases, the authors observed maximum aortic velocity exhibits a strong linear relationship, with the risk of mortality starting at velocities of 100 cm/s, whereas calculated aortic valve area was not related to mortality until the valve area was <1.5 cm2.
-
Interatrial Shunt Device for Heart Failure Disappoints
Placement of an interatrial shunt device in patients with heart failure with preserved or mildly reduced ejection fraction did not lower the rate of heart failure events or improve health status.
-
Recommendations Target Making Improvements in U.S. Organ Transplant System
The authors aimed for equity, transparency, and efficiency.
-
Physician Turnover Costs Millions in Excess Healthcare Spending
Each time a physician leaves his or her practice, that can lead to more than $86,000 in extra costs during the following year.
-
Psilocybin Produces Long-Term Antidepressive Benefits
Some patients sustained positive effects up to one year after treatment.
-
Better Cardiorespiratory Fitness Connected to Lower Risk for Developing Alzheimer’s
Yet another reason to stay physically active emerges.
-
Stress as a Reversible Risk Factor in Atrial Fibrillation Management
Researchers scrutinize this recognized but poorly defined relationship.
-
How Many Leads Are Abnormal?
The figure was obtained after cardiac catheterization for new chest pain. The rhythm is sinus bradycardia at ~50 beats/minute. All intervals are normal. The axis is leftward, but not enough to qualify as a hemiblock. There is no chamber enlargement.
-
Abrocitinib Tablets/Upadacitinib Extended-Release Tablets (Cibinqo/Rinvoq)
Abrocitinib and upadacitinib can be prescribed to treat adults with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic drug products, including biologics, or when using those therapies is inadvisable.